首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.
【24h】

Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

机译:载脂蛋白(apo)E4增强培养的神经元细胞中淀粉样β肽的产生:apoE结构作为潜在的治疗靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

Apolipoprotein (apo) E4 is a major risk factor for Alzheimer's disease, and many studies have suggested that apoE has isoform-specific effects on the deposition or clearance of amyloid beta (Abeta) peptides. We examined the effects of apoE isoforms on the processing of amyloid precursor protein (APP) and on Abeta production in rat neuroblastoma B103 cells stably transfected with human wild-type APP695 (B103-APP). Lipid-poor apoE4 increased Abeta production in B103-APP cells to a greater extent than lipid-poor apoE3 (60% vs. 30%) due to more pronounced stimulation of APP recycling by apoE4 than apoE3. The difference in Abeta production was abolished by preincubating the cells with the receptor-associated protein (25 nM), which blocks the low-density lipoprotein receptor-related protein (LRP) pathway, or by reducing LRP expression by small interference RNA. The differences were also attenuated by replacing Arg-61 with threonine in apoE4 or pretreating apoE4 with small molecules, both of which abolish apoE4 intramolecular domain interaction. Thus, apoE4 appears to modulate APP processing and Abeta production through both the LRP pathway and domain interaction. These findings provide insights into why apoE4 is associated with increased risk for Alzheimer's disease and may represent a potential target for drug development.
机译:载脂蛋白(apo)E4是阿尔茨海默氏病的主要危险因素,许多研究表明apoE对淀粉样β(Abeta)肽的沉积或清除具有同工型特异性作用。我们检查了载脂蛋白E亚型对淀粉样蛋白前体蛋白(APP)的加工以及对用人类野生型APP695(B103-APP)稳定转染的大鼠神经母细胞瘤B103细胞中Abeta产生的影响。贫脂apoE4比贫脂apoE3更大程度地增加了B103-APP细胞中Abeta的产量(60%比30%),这是因为apoE4比apoE3更明显地刺激了APP循环。通过将细胞与受体相关蛋白(25 nM)预孵育来消除Abeta产生的差异,该蛋白可阻断低密度脂蛋白受体相关蛋白(LRP)途径,或通过小干扰RNA降低LRP表达。通过用apoE4中的苏氨酸替代Arg-61或用小分子预处理apoE4,也消除了apoE4分子内域相互作用,从而减弱了差异。因此,apoE4似乎通过LRP途径和域相互作用来调节APP处理和Abeta产生。这些发现提供了对为什么apoE4与阿尔茨海默氏病风险增加相关联的见解,并可能代表药物开发的潜在目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号